Henry Meds and Shed both offer compounded GLP-1 medications for weight loss at competitive prices. Henry Meds has been in the market longer with broader recognition, while Shed differentiates with multiple medication formats and a 10% weight loss guarantee.
Platform Overview
Henry Meds is a multi-condition telehealth platform that offers GLP-1 weight loss treatment alongside its core focus areas of ED and hair loss treatment. Operating since 2021, Henry Meds has built a large patient base by providing affordable access to a range of men's health medications, with GLP-1 weight loss added as the market expanded. The platform charges $249-$449 per month for its weight loss programs and uses a nurse practitioner-led model for most clinical interactions. Henry Meds has been recognized for accessibility and competitive pricing, though its weight loss program is one of several service lines rather than the platform's primary focus. The FDA's obesity treatment framework supports the GLP-1 medications Henry Meds prescribes.
Shed is a telehealth platform built exclusively around GLP-1 weight loss treatment, offering semaglutide and tirzepatide programs at $199-$499 per month. Unlike multi-condition platforms, Shed's singular focus on weight loss means every element of its clinical protocols, coaching systems, and patient support infrastructure is optimized for that outcome. The platform's 10% body weight loss guarantee reflects this confidence in its focused approach. The
CDC's research on effective weight management underscores that program-specific support improves patient adherence and outcomes - a principle that informs Shed's specialist model.
Pricing Comparison
Henry Meds prices its weight loss programs at $249-$449 per month, positioning it in the mid-to-upper range of the GLP-1 telehealth market. The platform's pricing is straightforward, and patients can bundle weight loss treatment with other health services if needed. Henry Meds does not publicly advertise a weight loss guarantee, meaning patients who progress slowly bear the full financial risk of the investment. For patients managing multiple health conditions through a single telehealth provider, Henry Meds' bundled service model can represent efficiency savings compared to maintaining separate platforms for different conditions.
Shed's $199-$499 per month pricing is competitive with Henry Meds at the entry level, and the platform's 10% weight loss guarantee provides a meaningful financial risk buffer that Henry Meds does not offer. For patients whose sole focus is weight loss rather than multi-condition management, Shed's pricing delivers stronger value because every dollar spent is directed toward weight loss-specific support and clinical infrastructure. The
NIH's weight management guidance emphasizes that structured program support, which Shed's model emphasizes, improves cost-effectiveness of treatment.
Medication Options and Quality
Henry Meds offers both semaglutide and tirzepatide for weight loss, sourced through licensed compounding pharmacies. The platform's pharmacy network is a key operational component, and Henry Meds has established relationships with FDA-registered compounders. Because Henry Meds manages multiple therapeutic areas, its pharmacy operations are more complex than single-focus platforms. Clinical dosing follows standard GLP-1 titration protocols, with nurse practitioners adjusting doses based on patient response and tolerability. Tirzepatide's superior efficacy - with
NEJM trials showing 20%+ average weight loss - makes it the preferred option for patients who qualify.
Shed prescribes both semaglutide and tirzepatide through a clinical evaluation process that determines the most appropriate medication for each patient's profile. The platform's medication management is focused entirely on weight loss optimization, with dosing adjustments tied directly to weight loss progress and patient-reported side effects. Shed's clinical team monitors GLP-1 tolerability carefully, as nausea and GI side effects affect a significant portion of new patients. Both semaglutide and tirzepatide at Shed are dispensed through compliant pharmacy channels, with FDA-registered compounding pharmacies providing the supply.
Medical Team and Support
Henry Meds uses a nurse practitioner-led model for most patient interactions, with physician oversight available for complex cases. This model is cost-effective and appropriate for straightforward GLP-1 prescribing, though some patients prefer physician-direct care for their primary weight loss management. The platform provides messaging support and periodic check-ins, but its support structure is designed for efficiency across a large patient volume rather than intensive individualized coaching. Patients managing weight loss alongside other conditions through Henry Meds benefit from consolidated care, but weight-loss-specific coaching depth may be lighter than specialist-only platforms. JAMA research consistently shows that behavioral support intensity correlates with long-term weight maintenance.
Shed's medical team includes licensed physicians and nurse practitioners who specialize in weight loss treatment, supported by dedicated weight loss coaches who form a core part of the patient experience. This coaching layer - focused on behavioral adherence, goal-setting, and motivation - distinguishes Shed from platforms that treat GLP-1 prescribing as primarily a transactional clinical interaction. The
American Association of Clinical Endocrinology recommends combining pharmacotherapy with behavioral intervention for best obesity outcomes, and Shed's program structure directly implements this clinical guidance.
Weight Loss Approach and Programs
Henry Meds' weight loss approach is primarily pharmacological, centered on GLP-1 prescription management with supporting lifestyle guidance. The platform is well-suited for patients who are self-motivated and primarily need medication access and management, but who do not require intensive coaching or structured behavioral programs. Its multi-condition focus means the clinical team is experienced across diverse health issues, which can be valuable for patients whose weight is linked to other conditions like thyroid dysfunction or metabolic syndrome. However, patients seeking deeply personalized weight loss programming may find Henry Meds' approach less tailored than specialist platforms.
Research in Obesity journal shows combined approaches outperform medication-only models.
Shed's weight loss approach is built around its 10% body weight guarantee, which functions as both a clinical commitment and a program design anchor. Every coaching interaction, medication adjustment, and support touchpoint is oriented toward achieving and sustaining that guaranteed threshold. The platform combines GLP-1 pharmacotherapy with structured behavioral coaching that addresses the psychological and lifestyle factors contributing to weight challenges. This integrated model reflects the evidence-based consensus on optimal obesity treatment, and the guarantee provides patients with a concrete accountability framework that most telehealth platforms do not offer.
User Experience and Satisfaction
Henry Meds patients generally report satisfaction with the platform's ease of access and the efficiency of the prescription process. The onboarding experience is streamlined, and patients managing multiple conditions appreciate the consolidated portal. Some patients note that check-in frequency and coaching depth are lighter than they expected, particularly for the weight loss program. Henry Meds' strength is in accessibility and convenience rather than clinical intensity, and patients who approach it with realistic expectations about the level of support provided tend to report better outcomes. The platform's responsive messaging system is frequently cited as a positive feature.
Shed users consistently highlight the weight loss guarantee as a trust-building element that makes the initial commitment feel lower-risk. The platform's coaching check-ins are described as regular and proactive, with coaches initiating contact rather than waiting for patients to reach out. The clinical portal is designed specifically for weight loss tracking, making it easy for patients to monitor progress toward their guaranteed target. The
NIH's treatment adherence research confirms that regular provider contact significantly improves GLP-1 adherence rates - a finding that directly supports Shed's coaching model.
How We Tested Henry Meds vs Shed
Our Comparison Methodology
This comparison is based on complete analysis supplemented by peer-reviewed research on weight loss treatment.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), obesity treatment guidelines from the American Association of Clinical Endocrinology, and clinical efficacy data from The New England Journal of Medicine.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 medication efficacy from Obesity and behavioral support impact from JAMA.
Pricing Analysis: All pricing reflects published rates as of March 2026, verified through official platform websites.
Service Verification: Platform capabilities, provider credentials, and service quality were evaluated through detailed review of service offerings.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Henry Meds vs Shed
Choose Henry Meds if: You need to manage weight loss alongside other health conditions (ED, hair loss) through a single telehealth platform. Henry Meds' multi-condition model offers consolidation convenience and competitive pricing for patients with multiple health goals.
Choose Shed if: Weight loss is your primary health objective and you want a specialist platform with outcome accountability. Shed's 10% weight loss guarantee and dedicated coaching provide superior focus and risk protection for patients whose sole priority is achieving meaningful weight loss results.
Bottom line: Henry Meds and Shed both provide effective GLP-1 access, but serve different patient profiles. Henry Meds is the better choice for patients who value multi-condition convenience, while Shed is the stronger option for patients who want a specialist weight loss program with a guaranteed outcome. For most patients whose only goal is weight loss, Shed's dedicated focus and outcome guarantee make it the more compelling choice.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
